Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
63
AVXL Quote, Financials, Valuation and Earnings
Last price:
$10.86
Seasonality move
:
18.88%
Day range:
$10.82 - $12.48
52-week range:
$3.25 - $12.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.67x
Volume:
2.9M
Avg. volume:
1.7M
1-year change:
21.45%
Market cap:
$921.9M
Revenue:
--
EPS (TTM):
-$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | -$0.17 | -- | -72.73% | $35.47 |
|
CDMO
Avid Bioservices
|
$34.7M | -$0.10 | 25.43% | -55.56% | -- |
|
GALT
Galectin Therapeutics
|
-- | -- | -- | -- | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
SLS
SELLAS Life Sciences Group
|
-- | -$0.13 | -- | -57.33% | -- |
|
TCRT
Alaunos Therapeutics
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
$10.87 | $35.47 | $921.9M | -- | $0.00 | 0% | -- |
|
CDMO
Avid Bioservices
|
$12.26 | -- | $784.2M | -- | $0.00 | 0% | 5.18x |
|
GALT
Galectin Therapeutics
|
$0.84 | -- | $52.8M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.38 | -- | $4.6M | -- | $0.00 | 0% | 1.49x |
|
SLS
SELLAS Life Sciences Group
|
$0.93 | -- | $65.4M | -- | $0.00 | 0% | -- |
|
TCRT
Alaunos Therapeutics
|
$1.96 | -- | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | 3.153 | -- | -- |
|
CDMO
Avid Bioservices
|
77.48% | 0.583 | 24.2% | 0.86x |
|
GALT
Galectin Therapeutics
|
-- | -3.116 | -- | -- |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
SLS
SELLAS Life Sciences Group
|
-- | 0.853 | -- | -- |
|
TCRT
Alaunos Therapeutics
|
-- | 2.640 | -- | 2.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AVXL
Anavex Life Sciences
|
-- | -$14.3M | -- | -- | -- | -$6.7M |
|
CDMO
Avid Bioservices
|
-$2M | -$12.6M | -59.75% | -143.94% | -42.2% | $547K |
|
GALT
Galectin Therapeutics
|
-- | -$9.1M | -- | -- | -- | -$8.5M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
SLS
SELLAS Life Sciences Group
|
-- | -$7.3M | -- | -- | -- | -$7.8M |
|
TCRT
Alaunos Therapeutics
|
-- | -$1.2M | -189.69% | -189.69% | -28225% | -$781K |
Anavex Life Sciences vs. Competitors
-
Which has Higher Returns AVXL or CDMO?
Avid Bioservices has a net margin of -- compared to Anavex Life Sciences's net margin of -51.99%. Anavex Life Sciences's return on equity of -- beat Avid Bioservices's return on equity of -143.94%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.14 -- CDMOAvid Bioservices-6.11% -$0.27 $199M -
What do Analysts Say About AVXL or CDMO?
Anavex Life Sciences has a consensus price target of $35.47, signalling upside risk potential of 226.33%. On the other hand Avid Bioservices has an analysts' consensus of -- which suggests that it could grow by 5.02%. Given that Anavex Life Sciences has higher upside potential than Avid Bioservices, analysts believe Anavex Life Sciences is more attractive than Avid Bioservices.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 CDMOAvid Bioservices0 0 0 -
Is AVXL or CDMO More Risky?
Anavex Life Sciences has a beta of 0.729, which suggesting that the stock is 27.09% less volatile than S&P 500. In comparison Avid Bioservices has a beta of 1.444, suggesting its more volatile than the S&P 500 by 44.417%.
-
Which is a Better Dividend Stock AVXL or CDMO?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avid Bioservices offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Avid Bioservices pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or CDMO?
Anavex Life Sciences quarterly revenues are --, which are smaller than Avid Bioservices quarterly revenues of $33.5M. Anavex Life Sciences's net income of -$11.6M is higher than Avid Bioservices's net income of -$17.4M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Avid Bioservices's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 5.18x for Avid Bioservices. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.6M CDMOAvid Bioservices5.18x -- $33.5M -$17.4M
-
Which has Higher Returns AVXL or GALT?
Galectin Therapeutics has a net margin of -- compared to Anavex Life Sciences's net margin of --. Anavex Life Sciences's return on equity of -- beat Galectin Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.14 -- GALTGalectin Therapeutics-- -$0.18 -- -
What do Analysts Say About AVXL or GALT?
Anavex Life Sciences has a consensus price target of $35.47, signalling upside risk potential of 226.33%. On the other hand Galectin Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1208.59%. Given that Galectin Therapeutics has higher upside potential than Anavex Life Sciences, analysts believe Galectin Therapeutics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 GALTGalectin Therapeutics0 0 0 -
Is AVXL or GALT More Risky?
Anavex Life Sciences has a beta of 0.729, which suggesting that the stock is 27.09% less volatile than S&P 500. In comparison Galectin Therapeutics has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.07%.
-
Which is a Better Dividend Stock AVXL or GALT?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galectin Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Galectin Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or GALT?
Anavex Life Sciences quarterly revenues are --, which are smaller than Galectin Therapeutics quarterly revenues of --. Anavex Life Sciences's net income of -$11.6M is lower than Galectin Therapeutics's net income of -$11.2M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Galectin Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus -- for Galectin Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.6M GALTGalectin Therapeutics-- -- -- -$11.2M
-
Which has Higher Returns AVXL or OGEN?
Oragenics has a net margin of -- compared to Anavex Life Sciences's net margin of --. Anavex Life Sciences's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.14 -- OGENOragenics-- -$0.38 -- -
What do Analysts Say About AVXL or OGEN?
Anavex Life Sciences has a consensus price target of $35.47, signalling upside risk potential of 226.33%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 23709.52%. Given that Oragenics has higher upside potential than Anavex Life Sciences, analysts believe Oragenics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 OGENOragenics0 0 0 -
Is AVXL or OGEN More Risky?
Anavex Life Sciences has a beta of 0.729, which suggesting that the stock is 27.09% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock AVXL or OGEN?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or OGEN?
Anavex Life Sciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Anavex Life Sciences's net income of -$11.6M is lower than Oragenics's net income of -$2.5M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus 1.49x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.6M OGENOragenics1.49x -- -- -$2.5M
-
Which has Higher Returns AVXL or SLS?
SELLAS Life Sciences Group has a net margin of -- compared to Anavex Life Sciences's net margin of --. Anavex Life Sciences's return on equity of -- beat SELLAS Life Sciences Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.14 -- SLSSELLAS Life Sciences Group-- -$0.10 -- -
What do Analysts Say About AVXL or SLS?
Anavex Life Sciences has a consensus price target of $35.47, signalling upside risk potential of 226.33%. On the other hand SELLAS Life Sciences Group has an analysts' consensus of -- which suggests that it could grow by 527.58%. Given that SELLAS Life Sciences Group has higher upside potential than Anavex Life Sciences, analysts believe SELLAS Life Sciences Group is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 SLSSELLAS Life Sciences Group0 0 0 -
Is AVXL or SLS More Risky?
Anavex Life Sciences has a beta of 0.729, which suggesting that the stock is 27.09% less volatile than S&P 500. In comparison SELLAS Life Sciences Group has a beta of 2.391, suggesting its more volatile than the S&P 500 by 139.11%.
-
Which is a Better Dividend Stock AVXL or SLS?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. SELLAS Life Sciences Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or SLS?
Anavex Life Sciences quarterly revenues are --, which are smaller than SELLAS Life Sciences Group quarterly revenues of --. Anavex Life Sciences's net income of -$11.6M is lower than SELLAS Life Sciences Group's net income of -$7.1M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while SELLAS Life Sciences Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus -- for SELLAS Life Sciences Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.6M SLSSELLAS Life Sciences Group-- -- -- -$7.1M
-
Which has Higher Returns AVXL or TCRT?
Alaunos Therapeutics has a net margin of -- compared to Anavex Life Sciences's net margin of -28225%. Anavex Life Sciences's return on equity of -- beat Alaunos Therapeutics's return on equity of -189.69%.
Company Gross Margin Earnings Per Share Invested Capital AVXLAnavex Life Sciences-- -$0.14 -- TCRTAlaunos Therapeutics-- -$0.70 $3.8M -
What do Analysts Say About AVXL or TCRT?
Anavex Life Sciences has a consensus price target of $35.47, signalling upside risk potential of 226.33%. On the other hand Alaunos Therapeutics has an analysts' consensus of -- which suggests that it could grow by 10385.22%. Given that Alaunos Therapeutics has higher upside potential than Anavex Life Sciences, analysts believe Alaunos Therapeutics is more attractive than Anavex Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings AVXLAnavex Life Sciences2 0 0 TCRTAlaunos Therapeutics0 0 0 -
Is AVXL or TCRT More Risky?
Anavex Life Sciences has a beta of 0.729, which suggesting that the stock is 27.09% less volatile than S&P 500. In comparison Alaunos Therapeutics has a beta of -0.444, suggesting its less volatile than the S&P 500 by 144.433%.
-
Which is a Better Dividend Stock AVXL or TCRT?
Anavex Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alaunos Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anavex Life Sciences pays -- of its earnings as a dividend. Alaunos Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AVXL or TCRT?
Anavex Life Sciences quarterly revenues are --, which are smaller than Alaunos Therapeutics quarterly revenues of $4K. Anavex Life Sciences's net income of -$11.6M is lower than Alaunos Therapeutics's net income of -$1.1M. Notably, Anavex Life Sciences's price-to-earnings ratio is -- while Alaunos Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anavex Life Sciences is -- versus -- for Alaunos Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AVXLAnavex Life Sciences-- -- -- -$11.6M TCRTAlaunos Therapeutics-- -- $4K -$1.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
